135 related articles for article (PubMed ID: 23458598)
1. Suppressing commercial speech is not in the best interests of physicians and patients.
Chressanthis G; Khedkar P; Jain N; Poddar P; Seiders M
J Clin Hypertens (Greenwich); 2013 Mar; 15(3):219-20. PubMed ID: 23458598
[No Abstract] [Full Text] [Related]
2. Should physicians rely on pharmaceutical detailing for their education?
van Schalkwyk JM; Turner MJ
J Clin Hypertens (Greenwich); 2013 Mar; 15(3):218. PubMed ID: 23458597
[No Abstract] [Full Text] [Related]
3. Drug detailing in academic medical centers: regulating for the right reasons, with the right evidence, at the right time.
Steinman MA; Schillinger D
Am J Bioeth; 2010 Jan; 10(1):21-3. PubMed ID: 20077331
[No Abstract] [Full Text] [Related]
4. Can access limits on sales representatives to physicians affect clinical prescription decisions? A study of recent events with diabetes and lipid drugs.
Chressanthis GA; Khedkar P; Jain N; Poddar P; Seiders MG
J Clin Hypertens (Greenwich); 2012 Jul; 14(7):435-46. PubMed ID: 22747616
[TBL] [Abstract][Full Text] [Related]
5. Doctors behaving badly?
Tattersall MH; Kerridge IH
Med J Aust; 2006 Sep; 185(6):299-300. PubMed ID: 16999666
[No Abstract] [Full Text] [Related]
6. Conflict of interest: the elephant in your practice.
Kaliski S
Afr J Psychiatry (Johannesbg); 2013 May; 16(3):161, 163, 165. PubMed ID: 23739815
[No Abstract] [Full Text] [Related]
7. Physician Exposure to Direct-to-Consumer Pharmaceutical Marketing: Potential for Creating Prescribing Bias.
Brown JL
Am J Med; 2017 Jun; 130(6):e247-e248. PubMed ID: 28089801
[No Abstract] [Full Text] [Related]
8. Take this medicine: the legality of prescription incentive schemes.
Fanning J; Glover-Thomas N
Med Law Rev; 2010; 18(3):417-26. PubMed ID: 20739438
[No Abstract] [Full Text] [Related]
9. [Conflicts of interest: an academic proposal].
Lama A
Rev Med Chil; 2006 Jun; 134(6):800. PubMed ID: 17130959
[No Abstract] [Full Text] [Related]
10. No more free lunches.
Abbasi K; Smith R
BMJ; 2003 May; 326(7400):1155-6. PubMed ID: 12775587
[No Abstract] [Full Text] [Related]
11. [Editorial: Hebebrand, J., Blanz, B., Herpertz-Dahlmann, B. & Lehmkuhl, G. 2012. Increase in the abundance of medical treatments, ethical principles and conflicts of interest in cooperation with the pharmaceutical industry].
Frank R
Z Kinder Jugendpsychiatr Psychother; 2013 Mar; 41(2):145-9. PubMed ID: 23425616
[No Abstract] [Full Text] [Related]
12. The baby with the bathwater.
Buyske J
Arch Surg; 2010 Jun; 145(6):577. PubMed ID: 20575190
[No Abstract] [Full Text] [Related]
13. [Conflicts of interest, an insidious blight on medicine].
Altisent R
Aten Primaria; 2019 Oct; 51(8):469-470. PubMed ID: 31202475
[No Abstract] [Full Text] [Related]
14. Financial incentives and the prescription of newer vaccines by doctors in India.
Lodha R; Bhargava A
Indian J Med Ethics; 2010; 7(1):28-30. PubMed ID: 20166294
[No Abstract] [Full Text] [Related]
15. Doping Doctors: The Influence of the Marketing Departments of Pharmaceutical Companies on Physician and Researcher Behavior in Japan.
Ichikawa I; Clayton EW
Account Res; 2016; 23(4):245-53. PubMed ID: 26829657
[No Abstract] [Full Text] [Related]
16. Mixing Dinner and Drugs-Is It Ethically Contraindicated?
Essi DF
AMA J Ethics; 2015 Aug; 17(8):787-95. PubMed ID: 26270881
[No Abstract] [Full Text] [Related]
17. [Conflicts of interest in the medical profession].
Altisent R; Delgado-Marroquín MT; Astier-Peña MP
Aten Primaria; 2019 Oct; 51(8):506-511. PubMed ID: 31248656
[TBL] [Abstract][Full Text] [Related]
18. Sunshine Has Darkened my Worldview.
Alward WL
Am J Ophthalmol; 2017 Mar; 175():xii-xiii. PubMed ID: 28088286
[No Abstract] [Full Text] [Related]
19. New Swiss guidelines aim to curb big pharma's influence.
Hyde R
Lancet; 2013 Feb; 381(9865):441-2. PubMed ID: 23405415
[No Abstract] [Full Text] [Related]
20. Docking the tail that wags the dog: banning drug reps from academic medical facilities.
Millard WB
Ann Emerg Med; 2007 Jun; 49(6):785-91. PubMed ID: 17536244
[No Abstract] [Full Text] [Related]
[Next] [New Search]